Deazaneplanocin A Is a Promising Drug to Kill Multiple Myeloma Cells in Their Niche
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Deazaneplanocin A Is a Promising Drug to Kill Multiple Myeloma Cells in Their Niche
Authors
Keywords
-
Journal
PLoS One
Volume 9, Issue 9, Pages e107009
Publisher
Public Library of Science (PLoS)
Online
2014-09-26
DOI
10.1371/journal.pone.0107009
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival
- (2015) Renji Reghunathan et al. Oncotarget
- Antiestrogen-binding site ligands induce autophagy in myeloma cells that proceeds through alteration of cholesterol metabolism
- (2015) Brigitte Sola et al. Oncotarget
- GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic target
- (2014) N I Herath et al. Blood Cancer Journal
- Intratibial Injection of Human Multiple Myeloma Cells in NOD/SCID IL-2Rγ(Null) Mice Mimics Human Myeloma and Serves as a Valuable Tool for the Development of Anticancer Strategies
- (2013) Julia Schueler et al. PLoS One
- Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma
- (2012) A. Chaidos et al. BLOOD
- Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma
- (2012) S. Blotta et al. BLOOD
- Dysregulation of the Repressive H3K27 Trimethylation Mark in Head and Neck Squamous Cell Carcinoma Contributes to Dysregulated Squamous Differentiation
- (2012) O. M. Gannon et al. CLINICAL CANCER RESEARCH
- TP53 Genomic Status Regulates Sensitivity of Gastric Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A (DZNep)
- (2012) L. L. Cheng et al. CLINICAL CANCER RESEARCH
- Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells
- (2012) W. Fiskus et al. CLINICAL CANCER RESEARCH
- Senescence-associated secretory phenotype favors the emergence of cancer stem-like cells
- (2012) J Cahu et al. Cell Death & Disease
- The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML
- (2011) J. Zhou et al. BLOOD
- (-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells
- (2011) S. R. Choudhury et al. CARCINOGENESIS
- Aberrations of EZH2 in Cancer
- (2011) A. Chase et al. CLINICAL CANCER RESEARCH
- Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer
- (2011) Francesco Crea et al. Molecular Cancer
- Cell death assays for drug discovery
- (2011) Oliver Kepp et al. NATURE REVIEWS DRUG DISCOVERY
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Determinants of Sensitivity to DZNep Induced Apoptosis in Multiple Myeloma Cells
- (2011) Zhigang Xie et al. PLoS One
- EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis
- (2010) I. Velichutina et al. BLOOD
- Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation
- (2010) D. B. Yap et al. BLOOD
- The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells
- (2010) E. Martinez-Garcia et al. BLOOD
- Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway byNanoparticle Albumin-Bound–Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma
- (2010) Diana Cirstea et al. MOLECULAR CANCER THERAPEUTICS
- Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
- (2010) Ryan D Morin et al. NATURE GENETICS
- Polycomb Target Genes Are Silenced in Multiple Myeloma
- (2010) Antonia Kalushkova et al. PLoS One
- Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas
- (2010) C. J. Sneeringer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells
- (2009) W. Fiskus et al. BLOOD
- The potential role of epigenetic therapy in multiple myeloma
- (2009) Emma M. Smith et al. BRITISH JOURNAL OF HAEMATOLOGY
- EZH2 Is Essential for Glioblastoma Cancer Stem Cell Maintenance
- (2009) M.-L. Suva et al. CANCER RESEARCH
- DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation
- (2009) T. B. Miranda et al. MOLECULAR CANCER THERAPEUTICS
- Effect of autophagy on multiple myeloma cell viability
- (2009) B. Hoang et al. MOLECULAR CANCER THERAPEUTICS
- Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer
- (2009) Gijs van Haaften et al. NATURE GENETICS
- Therapeutic Potential of New 4-hydroxy-tamoxifen-Loaded pH-gradient Liposomes in a Multiple Myeloma Experimental Model
- (2009) Giorgia Urbinati et al. PHARMACEUTICAL RESEARCH
- Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance
- (2008) W. Matsui et al. CANCER RESEARCH
- A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect
- (2008) H. Rozemuller et al. HAEMATOLOGICA
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started